tazocin
tazocin.JPG

CLINICAL USE

Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

2.25–4.5 g every 6–8 hours

PHARMACOKINETICS

  • Molecular weight                           :Piperacillin: 539.5, Tazobactam: 322.3 (as sodium)
  • %Protein binding                           :Piperacillin: 20–30, Tazobactam: 20–30
  • %Excreted unchanged in urine     : Piperacillin: 60–80, Tazobactam: 80
  • Volume of distribution (L/kg)       :Piperacillin: 0.18–0.3, Tazobactam: 0.18–0.331
  • half-life – normal/ESRD (hrs)      :Piperacillin: 1/4–6, Tazobactam: 1/7

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : 4.5 g every 8–12 hours, or 2.25 g every 6 hours
  • <10           : 4.5 g every 12 hours, or 2.25 g every 8 hours

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR
  • <10           : mL/minute
  • HD                     :Dialysed. Dose as in GFR
  • <10           : mL/minute
  • HDF/high flux   :Dialysed. Dose as in GFR
  • <10           : mL/minute
  • CAV/VVHD      :Dialysed. Dose as in GFR=10–20 mL/minute, or 2.25 g every 6 hours,1 or 4.5 g every 12 hoursCVVhd/HDFDialysed: 2.25–3.375 g every 6 hours,1 or 4.5 g every 8 hours

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsReduced excretion of methotrexate – monitor methotrexate levels during concomitant treatmentEnhanced action of vecuronium and similar neuromuscular blocking agents

    ADMINISTRATION

    Reconstition

    Reconstitute each 4.5 g with 20 mL sterile water for injection or sodium chloride 0.9%

    Route

    IV

    Rate of Administration

    IV bolus over 3–5 minutes

    IV infusion

    over 20–30 minutes

    Comments

    May be given as an infusion in glucose 5% or sodium chloride 0.9%

    OTHER INFORMATION

    Sodium content is 2.79 mmol/g of injectionHas been used intraperitoneally for treatment of PD peritonitis at a concentration of 250 mg/LPatients with renal impairment are at a greater risk of neuromuscular excitability or convulsions that are associated with overdoseMay cause in vitro inactivation of aminoglycosides6–21% is removed by peritoneal dialysis and 30–50% by haemodialysis plus an extra 5% as the metabolite



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs